SCHEMBL936581

SCHEMBL936581

C#CC1=CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313750 0.92
SCHEMBL19743635 0.74 DRD2 (0.31)
SCHEMBL19743634 0.74 DRD2 (0.31)
SCHEMBL19743636 0.74 DRD2 (0.31)
SCHEMBL262240 0.72
SCHEMBL11277464 0.72
SCHEMBL6259313 0.72
SCHEMBL149920 0.72
SCHEMBL17958953 0.72
SCHEMBL3341155 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111198479-B Resist composition and resist pattern forming method 东京应化工业株式会社 2024-05-28 CN disclosed
CN-116670585-A Resist composition and resist pattern forming method 东京应化工业株式会社 2023-08-29 CN disclosed
CN-107844030-B Resist composition and method for forming resist pattern 东京应化工业株式会社 2023-04-25 CN disclosed
EP-2892534-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2021-08-04 EP disclosed
US-10301280-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2019-05-28 US disclosed
US-10227357-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2019-03-12 US disclosed
EP-2970265-B1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PLEXXIKON INC (US) 2018-08-08 EP disclosed
US-20180072722-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Opna Bio SA (CH) 2018-03-15 US disclosed
EP-2935248-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-02-28 EP disclosed
US-9856259-B2 Heterocyclic compounds and uses thereof PLEXXIKON INC. (US) 2018-01-02 US disclosed
WO-2011009934-A1 TRIS(1,2,3-TRIAZOL-4-YL)METHANE ORGANOMETALLIC COMPOUNDS AS CATALYSTS AND PROCESSES USING THEM. INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) (ES) 2011-01-27 WO disclosed
US-20090069569-A1 CYCLOADDITION OF AZIDES AND ALKYNES INSTITUT CATALA D'INVESTIGACIO QUIMICA (ES) 2009-03-12 US disclosed
EP-0751140-A2 Ene-yne unsaturated compounds as accelerators for hydrosilation DOW CORNING CORPORATION (US) 1997-01-02 EP disclosed
US-5493045-A SILICON HYDRIDE IS REACTED WITH AN UNSATURATED COMPOUND INPRESENCE OF PLATIMUM CATALYST DOW CORNING CORPORATION (US) 1996-02-20 US disclosed
US-4833157-A ANTIULCER AGENTS MILES INC. (US) 1989-05-23 US disclosed
US-4742080-A Therapeutic method for producing bronchodilation by administration of 15-deoxy-16-hydroxy prostaglandin esters MILES LABORATORIES, INC. (US) 1988-05-03 US disclosed
US-4415592-A ANTISECRETORY AND HYPOTENSIVE AGENTS MILES LABORATORIES, INC. (US) 1983-11-15 US disclosed
US-4331688-A Therapeutic method for inhibiting gastric secretion by administration of 15-deoxy-16-hydroxy prostaglandins MILES LABORATORIES, INC. (US) 1982-05-25 US disclosed
US-4275224-A BRONCHODIALATORS AND ANTI-GASTRIC SECRETION AGENTS MILES LABORATORIES, INC. (US) 1981-06-23 US disclosed
US-4132738-A BRONCHODILATORS, ANTISECRETORY AGENTS MILES LABORATORIES, INC. (US) 1979-01-02 US disclosed